Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

Business Wire May 4, 2023

Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting

Business Wire April 24, 2023

Acorda Launches INBRIJA® TV Commercial for Parkinson's Awareness Month

Business Wire April 3, 2023

Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A

Business Wire March 27, 2023

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire March 9, 2023

ESTEVE Launches INBRIJA® in Spain

Business Wire March 7, 2023

Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023

Business Wire March 6, 2023

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Business Wire February 14, 2023

Acorda Therapeutics to Present at Sequire Biotechnology Conference

Business Wire January 31, 2023

Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®

Business Wire January 5, 2023

Acorda Therapeutics Announces Revised Long-Term Financial Guidance

Business Wire December 22, 2022

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing

Business Wire December 20, 2022

Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash

Business Wire December 5, 2022

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

Business Wire November 11, 2022

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Business Wire November 4, 2022

Acorda Therapeutics Reports Third Quarter 2022 Financial Results

Business Wire November 1, 2022

Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance

Business Wire October 27, 2022

Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022

Business Wire October 25, 2022

Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.

Business Wire October 21, 2022

ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split

Business Wire October 19, 2022